Moderna CEO Stephane Bancel revealed during a Thursday interview on CNBC’s “Squawk Box” that Moderna anticipates a “base plan for efficacy” to be released in November, as the company has been saying for “many months.”
“If the infection rate in the country were to slow down in the next weeks, it could potentially be pushed out in a worst-case scenario in December,” he added.
The CEO’s comments follow US President Donald Trump’s repeated assertions that a vaccine will be available during October. Trump did not specify which vaccine effort he believed would be cleared by the US Food and Drug Administration.
Bancel explained to CNBC that it is unlikely that Moderna will have enough data to make an accurate assertion about the vaccine’s efficacy by October.
Menawhile, Pfizer CEO Albert Bourla told CNBC on Monday that it is likely that his company will have a “conclusive efficacy result of our Phase 3 trial before the end of October.”
He clarified that he was not providing “official dates” and that results could come in “a week earlier” or “a week later,” during the week of the US presidential election.